Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Stupp

Showing results (291-300 of 314) with videos related to

Pageof 32
Sort By:
The Lancet. Oncology|February 29, 2024
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort studyAditya Rastogi, Gianluca Brugnara, Martha Foltyn-Dumitru, et al.
The Lancet. Oncology|July 2, 2021
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trialJawad Fares, Atique U Ahmed, Ilya V Ulasov, et al.
Nature Communications|December 16, 2025
Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxelMark W Youngblood, Abha Kumari, Yoon-Tae Kang, et al.
AJNR. American Journal of Neuroradiology|December 27, 2024
ReplyBenjamin M Ellingson, Francesco Sanvito, Whitney B Pope, et al.
JAMA|December 17, 2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew A Kanner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205Rimas V Lukas, Lijie Zhai, Kristen L Lauing, et al.
The Journal of Clinical Investigation|June 28, 2024
STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastomaHinda Najem, Spencer T Lea, Shashwat Tripathi, et al.
AJNR. American Journal of Neuroradiology|June 26, 2024
A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in AdultsBenjamin M Ellingson, Francesco Sanvito, Timothy F Cloughesy, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2012
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modalityRoger Stupp, Eric T Wong, Andrew A Kanner, et al.
The Oncologist|January 22, 2026
Age and sex as risk factors for health-related quality of life outcomes in patients with glioma: a CODAGLIO 2.0 analysisOgechukwu A Asogwa, Linda Dirven, Neil K Aaronson, et al.
Pageof 32

Showing results (291-300 of 314) with videos related to

Sort By:
Pageof 32
The Lancet. Oncology|February 29, 2024
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort studyAditya Rastogi, Gianluca Brugnara, Martha Foltyn-Dumitru, et al.
The Lancet. Oncology|July 2, 2021
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trialJawad Fares, Atique U Ahmed, Ilya V Ulasov, et al.
Nature Communications|December 16, 2025
Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxelMark W Youngblood, Abha Kumari, Yoon-Tae Kang, et al.
AJNR. American Journal of Neuroradiology|December 27, 2024
ReplyBenjamin M Ellingson, Francesco Sanvito, Whitney B Pope, et al.
JAMA|December 17, 2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew A Kanner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205Rimas V Lukas, Lijie Zhai, Kristen L Lauing, et al.
The Journal of Clinical Investigation|June 28, 2024
STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastomaHinda Najem, Spencer T Lea, Shashwat Tripathi, et al.
AJNR. American Journal of Neuroradiology|June 26, 2024
A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in AdultsBenjamin M Ellingson, Francesco Sanvito, Timothy F Cloughesy, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2012
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modalityRoger Stupp, Eric T Wong, Andrew A Kanner, et al.
The Oncologist|January 22, 2026
Age and sex as risk factors for health-related quality of life outcomes in patients with glioma: a CODAGLIO 2.0 analysisOgechukwu A Asogwa, Linda Dirven, Neil K Aaronson, et al.
Pageof 32